KONEXBiotech & Pharma446440

Epi Biotech

₩4,990▼ 14.99%2026-11-18 close
Market Cap
₩11.5B
Turnover
₩988,020
Volume
198 shares
Shares out.
2.3M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Early-Stage Hair-Loss Pipeline, Strained Balance Sheet

Epi Biotech is at an early clinical stage with its dermal papilla cell therapy EPI-001; revenue has grown and operating losses have narrowed, but book equity is negative.

  1. 1

    On a 2025 standalone basis, revenue was KRW 1,929 million, operating loss KRW 1,486 million and net loss KRW 1,909 million.

  2. 2

    Total liabilities were reported at KRW 17,201 million and total equity at negative KRW 11,904 million for the same period.

  3. 3

    EPI-001 completed first-patient dosing in its Phase 1/2a trial on April 21, 2026, and on June 23, 2026 decided to enter Phase 1 cohort 2 after a safety review committee assessment.

  4. 4

    As of a May 2025 report, the company said it was preparing a KOSDAQ transfer listing, while transfer listings in 2025 numbered only four, the lowest in 11 years.

  5. 5

    As of 17:02 KST on October 27, 2026, the share price was KRW 19,500 and market capitalization KRW 45.0 billion, while turnover was only KRW 97,500, indicating very thin trading.

02

Business structure

Epi Biotech, founded in 2015, started as a hair-loss specialist and has focused on developing drugs based on dermal papilla cells. The company listed on the Konex market on July 31, 2023.

Its core pipeline comprises the autologous dermal papilla cell therapy EPI-001, the allogeneic cell therapy EPI-008, the CXCL12-neutralizing antibody EPI-005 and the RIPK1 inhibitor EPI-002.

CEO Sung Jong-hyuk said dermal papilla cells are the key regulators of the hair growth cycle and that the company is developing the first therapy to use them.

The autologous EPI-001 is aimed at faster commercialization through regenerative-medicine tracks in Korea and China, while the allogeneic EPI-008 targets global expansion through a new-drug track.

The antibody EPI-005 targets conditions such as androgenetic alopecia and alopecia areata, with a goal of injections three to four times a year.

Current revenue comes from preclinical CRO services, cell-line sales and functional hair-loss cosmetics, and a contract with a US biotech at the end of 2024 marked its first overseas order.

In 2023 the company obtained an advanced biopharmaceutical manufacturing license from the Ministry of Food and Drug Safety, laying the groundwork for clinical-sample production and a CDMO business.

On competition, the CEO named Japan's Shiseido as a comparison, saying Shiseido uses cells from the outer follicle whereas Epi Biotech uses dermal papilla cells.

03

Recent trends

On a 2025 standalone basis, revenue was KRW 1,929 million, operating loss KRW 1,486 million and net loss KRW 1,909 million. According to FnGuide, operating losses narrowed from KRW 5.3 billion in 2022 to KRW 4.6 billion in 2023 and KRW 3.0 billion in 2024, when revenue was KRW 0.7 billion.

At the end of 2025, total assets were KRW 5,297 million, but total liabilities of KRW 17,201 million and total equity of negative KRW 11,904 million were reported, indicating full capital impairment. We could not confirm the composition of the sharp rise in liabilities, so we withhold interpretation.

The share price was KRW 13,960 at 16:10 KST on March 31, 2026. At 17:02 KST on October 27, 2026 the price was KRW 19,500, down 2.50% from the prior close, and market capitalization was KRW 45.0 billion. Turnover at that time was only KRW 97,500, so price moves on thin order books can be large.

On the clinical side, EPI-001 completed first-patient dosing in its Phase 1/2a trial on April 21, 2026, and on June 23, 2026 the trial moved to cohort 2 after the low-dose safety assessment in cohort 1, with a stated aim of starting Phase 2a enrollment within 2026.

The board resolved on October 14, 2026 to convene an extraordinary general meeting on November 25, 2026 to consider electing a non-executive director and an independent director.

04

Outlook

The near-term focus is whether safety data continue to accumulate across the dose-escalation cohorts of the EPI-001 Phase 1 trial. The Phase 2a portion is reportedly designed to randomize subjects 2:1 between EPI-001 and placebo, with hair count and diameter assessed over follow-up of up to 48 weeks.

Efficacy data are therefore some way off. The company's strategy is to pursue an out-licensing deal for EPI-001 once Phase 1/2a results emerge, and to seek a joint-research partner for EPI-005 at the preclinical entry stage. It also intends to time the KOSDAQ transfer listing around these milestones.

The timeline has slipped against earlier plans. The company once expected to complete the Phase 1/2a trial by the end of 2025, but first-patient dosing took place in April 2026. Eugene Investment & Securities notes that the KOSDAQ transfer-listing market is shrinking sharply along with the Konex market.

The company registered a key patent for a chemotherapy-induced hair-loss treatment in January 2026 and a core patent for allogeneic dermal papilla cell therapy in April 2026, widening its intellectual-property base.

The business indicators to watch are continued revenue growth, adherence to the clinical timeline and changes in the capital structure; we could not confirm any additional financing plan.

05

Bull factors

Entry into a first-of-its-kind trial

According to a report, this is the world's first clinical trial of an autologous dermal papilla cell therapy for hair loss. EPI-001 completed first-patient dosing in April 2026 and moved to cohort 2 after a safety review committee assessment. Passing the early safety step shows that development is actually progressing.

Multi-modality pipeline

The company holds autologous and allogeneic cell therapies, a neutralizing antibody and a small-molecule inhibitor, so it does not depend on a single mechanism. In 2026 it also registered patents related to chemotherapy-induced hair loss and allogeneic dermal papilla cell therapy.

The CEO said its goals at an overseas event were licensing of the antibody and synthetic-drug assets and business development for its AI-based Hair.I platform. A licensing deal, if concluded, would offer external validation of the preclinical assets.

Revenue growth and narrowing operating loss

According to FnGuide, operating loss narrowed from KRW 5.3 billion in 2022 to KRW 3.0 billion in 2024. On a 2025 standalone basis, revenue was KRW 1,929 million against an operating loss of KRW 1,486 million. CRO services, cell-line sales and functional cosmetics drove revenue, and overseas orders have begun. The more established these non-R&D revenue lines become, the greater the room for operating-loss improvement.

06

Bear factors

Full capital impairment and higher liabilities

At the end of 2025, standalone total equity was negative KRW 11,904 million, total liabilities KRW 17,201 million and total assets KRW 5,297 million. The gap between book equity and the KRW 45.0 billion market capitalization is very large.

The composition and repayment terms of the added liabilities should be checked in filings, and the way the balance sheet is repaired could dilute existing shareholders.

Early-stage trial and schedule slippage

EPI-001 is currently in an early dose-escalation stage evaluating safety and tolerability. Hair-growth efficacy has not yet been demonstrated. The company once expected to finish the Phase 1/2a trial by the end of 2025, yet first-patient dosing was completed only in April 2026.

Cell therapies involve demanding culture and administration processes, so further delays in later stages are possible.

Thin liquidity and transfer-listing uncertainty

As of 17:02 KST on October 27, 2026, turnover was only KRW 97,500, meaning almost no trading took place. Transfer listings in 2025 numbered four, the lowest in 11 years. If the KOSDAQ transfer is delayed, liquidity improvement and funding routes could remain limited.

07

Risk factors

Clinical and regulatory

The Phase 1 trial centers on safety, and efficacy will only be tested from Phase 2a onward. The Phase 2a portion is reportedly placebo-controlled with randomization, so results falling short of expectations cannot be ruled out.

Autologous cell therapies are manufactured patient by patient, which adds quality-control and regulatory burdens.

Financial

Total equity was reported at negative KRW 11,904 million at the end of 2025, and operating and net losses continue. Funding clinical costs requires external financing, which could bring dilution or interest burdens depending on terms.

We could not confirm further financing plans or the composition of liabilities, so future filings should be monitored.

Market and liquidity

The Konex market is thinly traded, so even small orders can move the price sharply. Along with the Konex contraction, the KOSDAQ transfer-listing market is also declining. Financial requirements could become a variable in the transfer review, though we could not confirm the company's status against specific criteria.

08

Overall view

Epi Biotech is a hair-loss specialist developing autologous and allogeneic dermal papilla cell therapies alongside antibody and small-molecule candidates. Its lead candidate EPI-001 completed first-patient dosing in April 2026 and decided in June of the same year to enter cohort 2, so early clinical work is under way.

On a 2025 standalone basis, revenue grew to KRW 1,929 million and operating loss narrowed to KRW 1,486 million. At the same time, total equity was negative KRW 11,904 million, making the capital structure the largest uncertainty. The bear case rests on unproven efficacy and an unfavorable transfer-listing environment.

The bull case points to clinical progress, a widening patent base and overseas CRO orders. Readers should form their own view after checking follow-up filings on the clinical timeline and capital structure.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. m.news.nate.com
  2. digitaltoday.co.kr
  3. mt.co.kr
  4. mt.co.kr
  5. m.yakup.com
  6. comp.fnguide.com
  7. news.mt.co.kr
  8. eugenefn.com
  9. pharm.edaily.co.kr
  10. pharm.edaily.co.kr
  11. medifonews.com
  12. medifonews.com
  13. mt.co.kr
  14. pharmnews.com
  15. synapse.patsnap.com

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis